Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Iannitto

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
European Journal of Haematology|February 29, 2020
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world studyEmilio Iannitto, Alessandra Romano, Potito Rosario Scalzulli, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
American Journal of Hematology|April 5, 2013
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Sonia Fabris, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
European Journal of Haematology|February 29, 2020
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world studyEmilio Iannitto, Alessandra Romano, Potito Rosario Scalzulli, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
American Journal of Hematology|April 5, 2013
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Sonia Fabris, et al.
Pageof 7